ES3035604T3 - Forms and compositions of inhibitors of plasma kallikrein - Google Patents

Forms and compositions of inhibitors of plasma kallikrein

Info

Publication number
ES3035604T3
ES3035604T3 ES21724430T ES21724430T ES3035604T3 ES 3035604 T3 ES3035604 T3 ES 3035604T3 ES 21724430 T ES21724430 T ES 21724430T ES 21724430 T ES21724430 T ES 21724430T ES 3035604 T3 ES3035604 T3 ES 3035604T3
Authority
ES
Spain
Prior art keywords
compound
pattern
solid form
xrpd
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21724430T
Other languages
English (en)
Spanish (es)
Inventor
Suresh Kumar Tipparaju
Jeffrey Scott Depue
Helge Alfred Reisch
Samuel Alexander Stratford
Joseph Stephen Harris
Sarah Jocelyn Fink
Nikolaos Papaioannou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES3035604T3 publication Critical patent/ES3035604T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES21724430T 2020-04-17 2021-04-16 Forms and compositions of inhibitors of plasma kallikrein Active ES3035604T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011776P 2020-04-17 2020-04-17
PCT/US2021/027620 WO2021211930A1 (en) 2020-04-17 2021-04-16 Forms and compositions of inhibitors of plasma kallikrein

Publications (1)

Publication Number Publication Date
ES3035604T3 true ES3035604T3 (en) 2025-09-05

Family

ID=75870731

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21724430T Active ES3035604T3 (en) 2020-04-17 2021-04-16 Forms and compositions of inhibitors of plasma kallikrein

Country Status (9)

Country Link
US (1) US20230167132A1 (enExample)
EP (2) EP4136091B1 (enExample)
JP (2) JP2023522331A (enExample)
DK (1) DK4136091T3 (enExample)
ES (1) ES3035604T3 (enExample)
FI (1) FI4136091T3 (enExample)
PL (1) PL4136091T3 (enExample)
PT (1) PT4136091T (enExample)
WO (1) WO2021211930A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4494698A3 (en) * 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JP5069905B2 (ja) * 2003-01-21 2012-11-07 アプテュイト （ウエスト ラファイエット）、エルエルシー 新規な共結晶化
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
PT3650439T (pt) * 2010-07-23 2021-03-03 Gruenenthal Gmbh Sais ou cocristais de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol
EP2663647A4 (en) * 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途

Also Published As

Publication number Publication date
JP2025142238A (ja) 2025-09-30
FI4136091T3 (fi) 2025-07-25
DK4136091T3 (da) 2025-08-18
PL4136091T3 (pl) 2025-08-18
US20230167132A1 (en) 2023-06-01
EP4136091B1 (en) 2025-05-28
WO2021211930A1 (en) 2021-10-21
EP4623913A3 (en) 2025-12-24
JP2023522331A (ja) 2023-05-30
PT4136091T (pt) 2025-08-22
WO2021211930A8 (en) 2021-12-16
EP4623913A2 (en) 2025-10-01
EP4136091A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
ES2371549T3 (es) Montelukast en estado sólido.
ES2698298T3 (es) Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
US10752607B2 (en) Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitors
KR20130122031A (ko) Ｈｉｖ 인테그라제 억제제의 칼륨 염
JP2009544602A (ja) サイクリン依存性キナーゼ阻害剤の医学的使用
WO2020001420A1 (zh) 一类细胞坏死抑制剂及其制备方法和用途
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
TW200306809A (en) Compounds for the treatment of inflammatory disorders
TW201315727A (zh) 尿嘧啶衍生物及其醫藥用途
ES2993711T3 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US20240317746A1 (en) Crystalline forms of an azetidine parp1 inhibitor
RU2507203C1 (ru) Соединение, некоторые его новые формы, фармацевтические композиции на его основе и способы получения и применения
JP2016505071A (ja) ｛［１−シアノ−５−（４−クロロフェノキシ）−４−ヒドロキシ−イソキノリン−３−カルボニル］−アミノ｝−酢酸の結晶形態
US20240174669A1 (en) Crystalline forms of a parp1 inhibitor
CN110012667A (zh) 化合物(2S，3R)-2-(((2-(1，5-二甲基-6-氧代-1，6-二氢吡啶-3-基)-1-((四氢-2H-吡喃-4-基)甲基)-1H-苯并[d]咪唑-5-基)甲基)氨基)-3-羟基丁酸异丙酯乙二磺酸盐的结晶水合物
TW201713668A (zh) 吡啶化合物
CN118159535A (zh) 小分子sting拮抗剂
KR20250144991A (ko) Apj 수용체 활성을 갖는 화합물의 염 및 고체 형태
JP2025142238A (ja) 血漿カリクレインの阻害剤の形態及び組成物
CN117321042A (zh) 用于治疗炎症性疾病或癌症的氧代二氢吲哚化合物
JP2016513676A (ja) 化合物の多形および塩
JP5796872B2 (ja) 第Ｘａ因子阻害剤の結晶性塩
US20240262785A1 (en) Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds
WO2024175065A1 (zh) 一类含有芳基取代的cdk12/13的降解剂，及其制备方法、药物组合物和应用
WO2021211938A1 (en) Solid forms of inhibitors of plasma kallikrein